A Study of LY3451838 in Healthy Participants

Summary

The study has two parts. In Part A, single increasing doses of LY3451838 will be administered intravenously (into a vein). In Part B, a single dose of LY3451838 will be administered subcutaneously (just under the skin).

Conditions

• Healthy

Interventions

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered IV Part A

DRUG

LY3451838

Administered SC Part B

DRUG

Placebo

Administered IV in Part A and SC in Part B

Sponsors & Collaborators

• Eli Lilly and Company

  lead INDUSTRY

Principal Investigators

• Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

21 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2018-12-11

Primary Completion

2020-02-26

Completion

2020-02-26

Countries

• Singapore

Study Locations